Press Releases

Date Title and Summary View
Toggle Summary Zosano Pharma Announces Partnership Agreement with EVERSANA to Support the Launch and Commercialization of Qtrypta™
Agreement outlines commercialization and distribution execution strategy upon FDA approval EVERSANA to provide commercial services of approximately $250 million over 5 years FREMONT, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage
View HTML
Toggle Summary Zosano Pharma Reports Second Quarter 2020 Financial Results and Provides Corporate Update
FREMONT, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2020 , as well as recent business highlights.
View HTML
Toggle Summary Zosano Pharma to Present at the BTIG Biotechnology Conference 2020
FREMONT, Calif. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo , will present a company overview at the BTIG Biotechnology Conference 2020 on Tuesday,
View HTML
Toggle Summary Zosano Pharma to showcase new post-hoc analyses of Qtrypta’s (M207) clinical trial data comparing key efficacy results from the pivotal study and the open-label long term safety study on the 2020 American Headache Society’s Virtual Annual Scientific Meeting Platform
FREMONT, Calif. , June 13, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that new post-hoc efficacy analyses of Qtrypta TM , Zosano’s lead investigational product candidate for the acute treatment of migraine, will be
View HTML
Toggle Summary Zosano Pharma Announces Change to a Virtual Meeting Format for 2020 Annual Meeting of Stockholders
FREMONT, Calif. , June 11, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (Nasdaq:ZSAN) (the “Company” or “Zosano”), a clinical-stage biopharmaceutical company, today announced a change in the format of its Annual Meeting of Stockholders (“Annual Meeting”) from in-person to virtual-only.
View HTML
Toggle Summary Zosano Pharma Reports First Quarter 2020 Financial Results and Provides Corporate Update
FREMONT, Calif. , May 14, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2020 , as well as recent business highlights.
View HTML
Toggle Summary Zosano Pharma Announces the Appointment of Christine Matthews as Chief Financial Officer
FREMONT, Calif. , May 01, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Christine Matthews as the company’s chief financial officer (CFO). Ms. Matthews , who previously served as interim CFO, will be
View HTML
Toggle Summary Zosano Pharma Reports Fourth Quarter and Fiscal Year 2019 Financial Results
FREMONT, Calif. , March 13, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2019, as well as recent business highlights.
View HTML
Toggle Summary Zosano Pharma Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market
FREMONT, Calif. , March 06, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (Nasdaq:ZSAN) (“Zosano”), a clinical-stage biopharmaceutical company, today announced that it has closed its previously-announced registered direct offering priced at-the-market under Nasdaq rules of 11,903,506 shares
View HTML
Toggle Summary Zosano Pharma Announces $11 Million Registered Direct Offering Priced At-the-Market
FREMONT, Calif. , March 05, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (Nasdaq:ZSAN) (“Zosano”), a clinical-stage biopharmaceutical company, today announced that it has entered into definitive agreements with institutional investors for the issuance and sale in a registered direct offering
View HTML